High Risk of Non-cancer Mortality in Bladder Cancer Patients: Evidence from SEER-Medicaid

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Jun 3

PMID 37270459

Authors

Shunde Wang

Chengguo Ge

Affiliations

Soon will be listed here.

Abstract

Purpose: The objective of this study was to investigate non-cancer causes of death and associated risk factors after bladder cancer (BC) diagnosis.

Methods: Eligible BC patients were obtained from the SEER database. SEER*Stat software 8.3.9.2 was used to calculate the standardized mortality ratios (SMRs). The proportions of different non-cancer cause of death were calculated and analyzed in different follow-up periods. Multivariate competing risk model was used to analyze the risk factors for death of BC and non-cancer diseases.

Results: In total, 240,954 BC patients were included and 106,092 patients experienced death, with 37,205 (35.07%), 13,208 (12.45%) and 55,679 (52.48%) patients experienced BC, other cancer and non-cancer disease-related deaths, respectively. Overall SMR for BC patients who died from non-cancer diseases was 2.42 (95% CI [2.40-2.44]). Cardiovascular diseases were the most common non-cancer cause of death, followed by respiratory diseases, diabetes mellitus, and infectious diseases. Multivariate competing risk analysis identified the following high-risk factors for non-cancer mortality: age > 60 years, male, whites, in situ stage, pathological type of transitional cell carcinoma, not receiving treatment (including surgery, chemotherapy, or radiation), and widowed.

Conclusions: Cardiovascular diseases are the leading non-cancer cause of death in BC patients, followed by respiratory disease, diabetes mellitus and infectious diseases. Physicians should pay attention to the risk of death from these non-cancer diseases. Also, physicians should encourage patients to engage in more proactive self-surveillance and follow up.

Citing Articles

Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities: State-of-the-Art Review.

Taylor L, Hong A, Hahm K, Kim D, Smith-Morris C, Zaha V JACC CardioOncol. 2024; 6(3):363-380.

PMID: 38983375 PMC: 11229558. DOI: 10.1016/j.jaccao.2024.03.010.

The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.

Strobach D, Haimerl L, Mannell H, Stief C, Karl A, Grimm T J Clin Med. 2023; 12(21).

PMID: 37959213 PMC: 10648271. DOI: 10.3390/jcm12216749.

References

Dai Z, Tang M, Chen Y, Zhang T, Li J, Lv G . Incidence and Risk Factors for Cerebrovascular-Specific Mortality in Patients with Colorectal Cancer: A Registry-Based Cohort Study Involving 563,298 Patients. Cancers (Basel). 2022; 14(9). PMC: 9105882. DOI: 10.3390/cancers14092053. View

Guan T, Qiu Z, Su M, Yang J, Tang Y, Jiang Y . Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study. Front Oncol. 2021; 11:641955. PMC: 8147725. DOI: 10.3389/fonc.2021.641955. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Lam B, Srivastava R, Morvant J, Shankar S, Srivastava R . Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance. Cells. 2021; 10(11). PMC: 8620339. DOI: 10.3390/cells10113077. View

Zhang J, Chang S, Chiang M, Chiu K, Wu S . Survival Impact of Current-Smoking-Related COPD or COPD with Acute Exacerbation on Bladder Preservation through Concurrent Chemoradiotherapy for Muscle-Invasive Bladder Urothelial Carcinoma. J Pers Med. 2021; 11(10). PMC: 8539205. DOI: 10.3390/jpm11100958. View

Marrie R, Maxwell C, Mahar A, Ekuma O, McClintock C, Seitz D . Cancer Incidence and Mortality Rates in Multiple Sclerosis: A Matched Cohort Study. Neurology. 2020; 96(4):e501-e512. DOI: 10.1212/WNL.0000000000011219. View

Liu C, Sun J, Xu J, Qian X, Hong S, Xu M . Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis. Front Pharmacol. 2022; 13:865988. PMC: 9021395. DOI: 10.3389/fphar.2022.865988. View

Gill E, Sandhu G, Ward D, Perks C, Bryan R . The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. Int J Mol Sci. 2021; 22(20). PMC: 8539374. DOI: 10.3390/ijms222011150. View

Abou Dagher G, El Khuri C, Chehadeh A, Chami A, Bachir R, Zebian D . Are patients with cancer with sepsis and bacteraemia at a higher risk of mortality? A retrospective chart review of patients presenting to a tertiary care centre in Lebanon. BMJ Open. 2017; 7(3):e013502. PMC: 5353271. DOI: 10.1136/bmjopen-2016-013502. View

10.

Liyanage U, Moore T, Joo H, Tanaka Y, Herrmann V, Doherty G . Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002; 169(5):2756-61. DOI: 10.4049/jimmunol.169.5.2756. View

11.

Zhang Y, Pan X, Chen J, Cao A, Zhang Y, Xia L . Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies. Br J Cancer. 2020; 122(7):1085-1093. PMC: 7109112. DOI: 10.1038/s41416-020-0741-x. View

12.

Choi Y, Park Y, Hur K, Ha U, Hong S, Lee J . Duration of diabetes mellitus and risk of kidney and bladder cancer: a longitudinal nationwide cohort study. Am J Cancer Res. 2022; 12(8):4050-4061. PMC: 9441993. View

13.

Li J, Pang H, Sun Z, Zhao L, Bai C . Health status of middle-aged and older cancer survivors: a nationwide cross-sectional study from the China Health and Retirement Longitudinal Study (CHARLS). Ann Transl Med. 2020; 8(5):183. PMC: 7154473. DOI: 10.21037/atm.2020.01.105. View

14.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

15.

Klose K, Packeiser E, Muller P, Granados-Soler J, Schille J, Goericke-Pesch S . Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line. PLoS One. 2021; 16(9):e0257403. PMC: 8476037. DOI: 10.1371/journal.pone.0257403. View

16.

Jalanko T, de Jong J, Gibb E, Seiler R, Black P . Genomic Subtyping in Bladder Cancer. Curr Urol Rep. 2020; 21(2):9. DOI: 10.1007/s11934-020-0960-y. View

17.

Wang S, Ge C, Zhang J . Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study. J Cardiovasc Dev Dis. 2022; 9(8). PMC: 9409417. DOI: 10.3390/jcdd9080255. View

18.

Sturgeon K, Deng L, Bluethmann S, Zhou S, Trifiletti D, Jiang C . A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019; 40(48):3889-3897. PMC: 6925383. DOI: 10.1093/eurheartj/ehz766. View

19.

Wang Z, Ong W, Shen T, Sng J, Lata R, Mahendran R . Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. Singapore Med J. 2020; 63(4):209-213. PMC: 9251265. DOI: 10.11622/smedj.2020121. View

20.

Zhang H, Lin W, Chen D, Wang K, Tu W, Lin H . Cardiovascular and Other Competing Causes of Death in Male Breast Cancer Patients: A Population-Based Epidemiologic Study. Clin Interv Aging. 2021; 16:1393-1401. PMC: 8312508. DOI: 10.2147/CIA.S314689. View